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ABSTRACT: Antimicrobial susceptibility testing (AST) is a standard clinical procedure used to quantify antimicrobial re-
sistance (AMR). Currently, the gold standard method requires incubation for 18–24 h and subsequent inspection for growth 
by a trained medical technologist. We demonstrate an automated, cost-effective optical system that delivers early AST results, 
minimizing incubation time and eliminating human errors, while remaining compatible with standard phenotypic assay 
workflow. The system is composed of cost-effective components and eliminates the need for optomechanical scanning. A 
neural network processes the captured optical intensity information from an array of fiber optic cables to determine whether 
bacterial growth has occurred in each well of a 96-well microplate. When the system was blindly tested on isolates from 33 
patients with Staphylococcus aureus infections, 95.03% of all the wells containing growth were correctly identified using our 
neural network, with an average of 5.72 h of incubation time required to identify growth. 90% of all wells (growth and no-
growth) were correctly classified after 7 h, and 95% after 10.5 h. Our deep learning-based optical system met the FDA-defined 
criteria for essential and categorical agreements for all 14 antibiotics tested after an average of 6.13 h and 6.98 h, respectively. 
Furthermore, our system met the FDA criteria for major and very major error rates for 11 of 12 possible drugs after an average 
of 4.02 h, and 9 of 13 possible drugs after an average of 9.39 h, respectively. This system could enable faster, inexpensive, 
automated AST, especially in resource-limited settings, helping to mitigate the rise of global AMR.
Introduction 
Antimicrobial resistance (AMR) is estimated to cause over 
700,000 deaths annually, with 2.8 million cases and 35,000 
deaths in the United States alone.1,2 By 2050, the number of 
deaths due to AMR is projected to reach as many as 10 mil-
lion per year.1 A host of factors are contributing to the global 
rise in AMR, such as over-prescription and abuse of antibi-
otics (e.g. for viral infections),3,4 use of medically important 
antibiotics in agriculture for e.g. promotion of growth in 
livestock5 and prevention of disease in citrus trees,6 as well 
as economic and regulatory barriers to the development of 
new drugs.7 
One of the most crucial tools to treat patients infected 
with resistant bacteria, as well as to stem the tide of global 
AMR, is antimicrobial susceptibility testing (AST). AST is a 
laboratory procedure used to determine which antibiotics 
will work most effectively against a given patient’s bacterial 
infection. The gold standard method is broth microdilution 
(BMD), in which isolated patient bacteria are inoculated in 
growth medium along with a candidate antibiotic and incu-
bated for at least 18–24 h. BMD is usually performed in a 
96-well microplate, with a different antibiotic/concentra-
tion combination in each well. Neighboring wells contain 
successive two-fold dilutions of the same drug. After incu-
bation, each well is inspected visually by a trained medical 
technologist to determine whether growth has occurred, as 
indicated by the presence of turbidity in the well. The mini-
mum inhibitory concentration (MIC) for a given antibiotic is 
defined as the lowest concentration of the drug that suc-
cessfully prevents bacterial growth. The MIC is used to de-
termine the categorical susceptibility of the bacteria to the 
drug (susceptible, intermediate, or resistant) based on con-
centration cutoffs published by the Clinical & Laboratory 
Standards Institute (CLSI).8 
The lengthy incubation time (18–24 h or more) puts pa-
tients at risk because in the interim they may be prescribed 
powerful broad-spectrum antibiotics or antibiotics against 
which the organism is resistant. The need for a trained ex-
pert to manually read the plate strains laboratory resources 
and inevitably introduces human error/variability. Auto-
mated AST systems such as the bioMérieux Vitek 29 enable 
readings much earlier during incubation for certain bacteria 
and drugs, but these systems are relatively bulky, expensive 
(due to e.g. optomechanical scanning components and illu-
mination sources), and often require the use of proprietary 
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plates and drug panels, limiting their utility especially in re-
source-limited settings, where AMR is expected to take the 
largest toll.10 
Numerous alternative approaches have been investigated 
to address the shortcomings of conventional AST. The de-
creasing cost of whole-genome sequencing (WGS) has made 
it a potentially-viable option, and it has been shown to agree 
with BMD for certain bacteria-drug combinations.11–13 How-
ever, the cost remains prohibitive for most labs, even in de-
veloped countries, and there is a lack of standardization for 
AST protocols.14 In addition, unless all the resistance mech-
anisms in question for a given sample are linked to genes 
with well-characterized effects—such as the mecA gene in 
methicillin-resistant Staphylococcus aureus (MRSA)15—
WGS-based AST will provide an incomplete resistance pro-
file, limiting its applications, especially for emerging forms 
of resistance.16–18 Due to its ability to enable rapid, low-cost 
diagnostics using small sample volumes, microfluidic tech-
nology has also been investigated for AST. By confining bac-
teria to microscale channels or droplets, the incubation time 
required to identify the impact of antibiotics on bacterial 
growth can be shortened considerably.19–27 MICs can be de-
termined straight from positive cultures (without the addi-
tional overnight isolation step) in the case of urine samples, 
but not for more complex samples such as blood or spu-
tum.26,27 Additionally, these microfluidic approaches gener-
ally require new specialized consumables and a scanning 
microscopy system to monitor the sample during incuba-
tion, limiting their viability in resource-limited settings. 
Pure microscopy-based approaches have also been 
demonstrated for AST.28–34  Commercially available systems 
such as the Pheno (Accelerate Diagnostics)35 and the oCel-
loScope (BioSense Solutions)36 have developed a more com-
pact form factor compared to benchtop microscopes, but 
still require expensive objective lenses and optomechanical 
scanning components to read a 96-well plate. These sys-
tems also depend on knowledge of specific organism mor-
phologies and growth characteristics, limiting their use to 
certain types of bacteria. As an alternative, lensfree micros-
copy37–39 eliminates the need for objective lenses, thus re-
ducing costs and mitigating the spatial/focal drift these 
components can cause during time lapse imaging. Lensfree 
microscopy has been shown to detect bacteria over a wide 
field of view,40,41 but has not yet been demonstrated for AST. 
Previously, we also demonstrated a smartphone reader for 
AST plates after the incubation period to determine turbid-
ity results.42,43 These earlier works did not capture time 
lapse images of the samples and therefore were aimed to 
provide end-point readings, after the standard incubation 
period (e.g., 18–24 h). 
In this work, we demonstrate an automated, cost-effec-
tive optical system for the early detection and quantification 
of resistance in AST using deep learning. The device can be 
placed directly inside a standard benchtop incubator and 
automatically monitor growth in all 96 wells of a standard 
microplate during incubation. The plate is periodically illu-
minated by red, green, and blue LEDs, and the transmitted 
light is relayed by an array of plastic optical fibers beneath 
the plate to two Raspberry Pi cameras for imaging. A neural 
network uses the intensity information from the images to 
classify each well as either turbid or non-turbid over time. 
This system eliminates the need to wait 18–24 h or more, 
offers significant time savings and does not rely on a trained 
medical technologist for readings as is necessary for con-
ventional AST, while also being compact and cost-effective 
compared to commercially available automated AST sys-
tems.  
Our system was blindly tested on 33 unique clinical 
Staphylococcus aureus isolates, using a panel containing 
varying concentrations of 14 antibiotics. 95.03% of all wells 
containing growth were correctly identified, with an aver-
age of 5.72 h of incubation required to identify growth. 90% 
of all wells were correctly classified after 7 h, and 95% after 
10.5 h. The system met the FDA-defined criteria44 for essen-
tial and categorical agreement for all 14 drugs tested after 
an average of 6.13 h and 6.98 h, respectively. The system 
met FDA criteria for major and very major error rates for 11 
of 12 possible drugs after an average of 4.02 h, and 9 of 13 
possible drugs after an average of 9.39 h, respectively. For 
each one of the drugs that did not meet the FDA criteria, 
only a single major or very major error was made. Some of 
the major and very major errors may also be due to human 
errors in the ground truth reading. With additional training 
and testing samples, the FDA criteria could potentially be 
met for all drugs. This system could enable inexpensive, 
high-throughput AST in resource-limited settings, helping 
treat infected patients while curbing the rise of drug-re-
sistant bacteria. 
 
Results 
Imaging System Design 
The AST system (Figure 1a,b) is composed of cost-effective 
components: LEDs, plastic optical fibers, singlet lenses, 
Raspberry Pi computers and camera modules, and 3D 
printed housing. It can be placed inside any standard labor-
atory incubator (Figure 1c) and has a slot for the insertion 
of a standard 96-well microplate loaded with bacterial iso-
lates, growth medium, and candidate antibiotics at various 
concentrations (Figure 1d). Two adjacent 8x8 RGB LED ar-
rays illuminate the entire plate from above, with one LED 
centered over each well. A plastic diffuser beneath the LEDs 
ensures spatial uniformity of illumination over the wells, 
and the brightness of each LED is controlled by pulse width 
modulation to compensate for the fact that wells near the 
center of the plate receive more light (due to neighboring 
LEDs) than those at the edge. Wells containing bacterial 
growth scatter the incident illumination, while the wells 
with no growth allow the light to pass through mostly un-
obstructed. Below each well, a bundle of 21 plastic optical 
fibers (Figure 1e) relays the transmitted light to one of two 
larger bundles, which are each imaged by the combination 
of a singlet lens and a CMOS camera connected to a Rasp-
berry Pi computer. A sample image is shown in Figure 1f. 
Images are periodically captured over the course of an 18 h 
incubation, and examples of fiber intensity changes over 
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time for wells with and without turbidity are shown in Fig-
ures 1g-i.
Figure 1. (a) Schematic and (b) photo of the device. (c) Device inside an incubator. (d) 96-well plate being loaded. (e) Close-up of 21 
fibers under one well. (f) Image of fibers captured by the system. (g) Normalized fiber intensity change after 18 h incubation for two 
neighboring wells. Fiber intensities and neural network predicted probability of turbidity for (h) a turbid well and (i) a non-turbid 
well. The colormap corresponds to the random arrangement of fibers in each well.  The predicted growth probability on the right 
axis corresponds to the gray curve in each plot, which is the output of the neural network as a function of the incubation time. 
In addition to capturing images, the two Raspberry Pis syn-
chronously control the schedule of the illumination and im-
age capture during incubation (Figure 2). Every five 
minutes, the LEDs are turned on and an image is captured, 
enabling temporal sampling of potential growth while en-
suring that the bacteria are not exposed to phototoxic levels 
of light. The illumination cycles through the three LED col-
ors, so that the time between images of the same color is 15 
minutes. A quality control strain of S. aureus was run re-
peatedly in the system to ensure the MICs were in the ex-
pected ranges,45 indicating bacterial growth is not ham-
pered by the periodic illumination (see Table S1). 
The fiber array functions to demagnify the plate area, en-
abling imaging of all 96 wells without any optomechanical 
scanning components, while maintaining a compact form 
factor.42,43 In this case, the fibers provide a demagnification 
factor of ~7, while capturing spatial information within 
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each well, which is especially important for wells showing 
weak or atypical growth. The number of fibers per well (21) 
and the focal length of the singlet lenses (50 mm) were 
Figure 2. Image processing pipeline. Images are captured every 5 min under either red, green, or blue illumination. Images are reg-
istered and fiber intensities are extracted. A neural network uses the fiber intensities from the previous 1 h to predict the probability 
that each well is turbid at the current time point. 
selected to maximize the amount of information captured 
per well. To address future manufacturability concerns, the 
locations of each of the 21 fibers within the wells were not 
manually recorded and tracked during assembly. Instead, 
the rough position of the fibers within each well (and thus, 
the information content) was empirically determined post 
hoc from the training data (further detailed below). 
The entire device measures 175 × 450 × 192 mm and the 
cost of the components (including all optics, electronics, and 
3D printing) is under $500, which would drop significantly 
at higher manufacturing volume. Our system easily inte-
grates with a typical clinical workflow, using any standard 
laboratory incubator and standard 96-well microplates. To 
operate our system, a user simply inserts a plate (Figure 
1d), then starts the image acquisition program on one of the 
Raspberry Pi computers. Our system was successfully oper-
ated by five different clinical laboratory personnel. 
Image Processing and Neural Network Design 
The data processing pipeline is shown in Figure 2. For each 
image, only the pixels corresponding to the illumination 
color are used (either red, green, or blue from the Bayer 
color filter array). For each plate, all subsequent images are 
aligned with the first image of the corresponding color us-
ing intensity-based registration, to account for any drift that 
may occur due to e.g. plate insertion, thermal effects, struc-
tural vibrations, etc. The first image of each color is also 
used to locate each fiber using the circular Hough trans-
form, constrained by prior knowledge of the fiber grid lay-
out. Using these fiber locations, the intensity of each fiber in 
each image is determined by averaging over a circular mask 
with a radius of 8 pixels, significantly smaller than the ra-
dius of the fiber to avoid any edge effects. Each temporal fi-
ber intensity is denoised with a 30-minute moving averag-
ing filter and normalized to its average value over the first 
10 images during incubation (2.5 h), during which time de-
tectable turbidity is not expected to develop. These prepro-
cessing steps mitigate the effect of fiber intensity variation 
due to illumination, fiber polishing defects, off-axis effects, 
etc. 
A turbidity prediction is made for each well after each im-
age (every 5 min) starting after 2.5 h of incubation. The nor-
malized fiber intensities for all 3 illumination colors over 
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the previous one hour are fed into a neural network that 
outputs a predicted probability of turbidity in the well at the 
current time. This is referred to as the window slicing 
method in the time series classification literature.46 Any 
value above 0.5 is interpreted as turbid, while values below 
0.5 are interpreted as non-turbid. Examples of fiber intensity 
plots and blind testing network predictions are shown in 
Figures 3, S1, and S2. The turbidity classifications are then 
used to determine the MIC and susceptibility for each drug 
based on established clinical cutoffs.8 The neural network 
comprises 4 fully connected hidden layers of 128 neurons 
each, and a binary classification output layer (Figure S3). 
Batch normalization and dropout (probability 0.5) were 
used after each hidden layer to accelerate training and limit 
overfitting, respectively. The network was trained with the 
Adam optimizer at a starting learning rate of 1e-3, which 
was decreased after the validation loss failed to improve for 
20 epochs. In total, the network has 83,073 trainable pa-
rameters. Note that the network does not employ any spa-
tial convolutional layers because the information contained 
in the fiber bundle images is not shift-invariant: each fiber 
corresponds to a fixed region of the plate. This is the reason 
the extracted fiber intensities—as opposed to images— are 
used as the input to the network. The network does not re-
ceive any prior information about the well, drug, or drug 
concentration; it makes predictions in a “well-blind” man-
ner, which prevents it from overfitting to the specifics of the 
plates that were used in the experiments. 
Training neural networks via supervised learning re-
quires ground truth labels for every training sample. Be-
cause a ground truth reading can only be performed via vis-
ual inspection by the trained medical technologist after in-
cubation, ground truth labels were only available for the fi-
nal time point of each patient plate (~18 h). Labels for the 
training plates at every other image time point during incu-
bation were created manually by inspecting the fiber inten-
sity plots for each well, such as those in Figures 3, S1, and 
S2. While these labels do not constitute a ground truth, they 
are the best available proxy and were used to train the net-
work to identify turbidity effectively at an earlier time point 
within the incubation phase. Additionally, in certain in-
stances where the ground truth label after 18 h disagreed 
with the manual label, the label was changed for network 
training. This type of data cleaning is acceptable (and com-
mon) for training/validation data, especially when access to 
ground truth is not available, but certainly must not be (and 
was not) employed on blind testing data as it could bias re-
sults.  
As mentioned previously, the 21-fiber bundles under 
each well were assembled without precise control of the 
mapping of each fiber from the well to the image to make 
the device easier to potentially manufacture in large quan-
tities. In the imaged fiber bundles (Figure 1f), the fibers are 
grouped by well, but the fibers within each well are ran-
domly arranged. For each well, a “fiber order” was deter-
mined empirically, using the amount by which the fiber in-
tensities dropped in the presence of turbidity, averaged 
over the entire training set. The fibers that show the largest 
drop can be assumed to be near the center of the well, 
where growth will ultimately be strongest by the end of in-
cubation, while the fibers that show the smallest drop can 
be assumed to be near the edges of the well, where even 
strong growth will have a limited effect on transmission 
(due to the settling that occurs in the round-bottomed wells 
for Gram-positive bacteria). The resulting fiber ordering 
was used for training and blind testing of the network and 
can be seen in all fiber intensity plots. This fiber ordering 
ensures that the network learns a general, robust model of 
turbidity over all wells, instead of overfitting to the individ-
ual characteristics of the fibers of each well.  
While the total number of training samples, each repre-
senting a single time point from a single well from a single 
patient plate, was large (263,019), the number of clinical 
isolates from which the training data was gathered was 
smaller (51). The variability among isolates accounted for 
much of the diversity of the dataset, both because each iso-
late had a unique resistance profile and because each plate 
was incubated on a different day by a set of rotating techni-
cians. To ensure that the learned network model was robust 
to this isolate-to-isolate variability, we employed nine-fold 
cross-validation by randomly splitting the 51 clinical isolate 
plates into nine subsets and training nine models, where 
each model was trained on eight of the subsets and vali-
dated on the ninth. This process was repeated 50 times and 
the best model for each subset was selected to form a final 
composite “panel” of nine neural networks. This cross-vali-
dation/composite method (a type of model bagging)47,48 
was employed to ensure that no single isolate plate exerted 
undue influence on the final model, as could have been the 
case if only a single validation set were used. Additionally, 
training in nine folds ensured each model was trained on a 
large number of dates (e.g., 45), which we found to improve 
performance on the validation data (Figure S4). Training 
many models was feasible because the number of layers and 
weights is small compared to many state-of-the-art image 
classification networks, which contain hundreds of millions 
of parameters. All training of the models was performed on 
a desktop computer in TensorFlow without a graphics pro-
cessing unit (GPU), and in the future, due to improvements 
in computational power, could even be performed on the 
Raspberry Pi. 
Clinical Testing Results 
All experiments were performed at the UCLA Clinical Micro-
biology Laboratory by clinical staff, using 96-well micro-
plates containing a Gram-positive antibiotic panel. Staphy-
lococcus aureus isolates were prepared to a 0.5 McFarland 
standard in sterile water and then diluted in Mueller Hinton 
Broth. The diluted suspension was pipetted into all 96 wells 
and the plate was inserted into the AST system inside an in-
cubator. 96-well microplates contained antibiotics in pow-
der form pre-loaded into each well of the plate. Bacteria 
were pipetted into all 96 wells along with growth medium 
and inserted into the AST system inside an incubator. The 
plate was removed and ground truth reading was per-
formed after 18–19 h. Initial experiments were performed 
on 47 plates, each with a quality control strain of S. aureus 
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with a known resistance profile to ensure the system was 
functioning properly and the bacteria were not experienc-
ing phototoxicity (Table S1). The MICs obtained from these 
control runs showed that the antibiotic linezolid used in the 
plates did not perform as expected and failed the quality 
control assessment, so its wells were excluded from the 
Figure 3. Fiber intensities and the panel of neural networks’ predicted probability of turbidity on blind testing patient isolates of 
Staphylococcus aureus for ground truth (a) turbid and (b) non-turbid wells.
study. Any wells containing antimicrobials that do not have 
interpretive criteria for S. aureus and are not routinely used 
for clinical management (e.g. ceftriaxone) were also ex-
cluded from the study. Next, 51 plates, each containing a S. 
aureus isolate from a unique patient, were used to generate 
training and validation data for the neural network. 33 ad-
ditional patient plates were used for blind testing data. The 
blind testing plates were read after 18–19 h by two trained 
technologists and wells with discrepant readings between 
the technologists were not used for testing the system (Ta-
ble S2). A single technologist was used to determine the tur-
bidity ground truth for the training/validation data. 
Examples of fiber intensities and neural network turbid-
ity predictions for blindly tested patient plates are shown in 
Figures 3, S1, and S2. The average incubation time required 
to obtain a correct turbid prediction for each drug is shown 
in Figure 4a. 95.03% of all turbid wells were correctly iden-
tified by the network, with the average turbid well requiring 
just 5.72h of incubation to detect. The system detected tur-
bidity for oxacillin in an average of 4.5 h, while it required 9 
h on average for trimethoprim/sulfamethoxazole (Bac-
trim). Figure 4b shows the turbidity detection accuracy 
over time for all drugs. 90% of all wells were correctly clas-
sified after 7 h and 95% after 10.5 h. The MIC and suscepti-
bility predictions for each drug were compared to the FDA-
defined criteria for automated AST systems, namely essen-
tial agreement (EA), categorical agreement (CA), major er-
ror (maj) rate, and very major error (vmj) rate.44 EA is the 
percentage of patients for which a drug’s predicted MIC is 
within plus or minus one two-fold dilution of the ground 
truth. CA is the percentage of patients for which the pre-
dicted susceptibility category (susceptible/intermedi-
ate/resistant) matches the ground truth. Maj rate is the per-
centage of all susceptible infections misclassified as re-
sistant (i.e. false positive) and vmj rate is the percentage of 
all resistant infections misclassified as susceptible (i.e. false 
negative). The FDA requires automated AST systems to 
demonstrate EA and CA greater than 90%, and maj rate and 
vmj rate of no more than 3%. 
Figure 5 shows the blind testing results for EA, CA, maj 
rate, and vmj rate for each of the 14 drugs over the course 
of incubation. The legend in each plot indicates the number 
of valid samples in the denominator of the calculation for 
each drug. For EA/CA this is the number of blind testing pa-
tient plates for which there was agreement between the two 
human readers (out of a possible 33), and for maj/vmj rate 
it is the number of susceptible and resistant patient infec-
tions for which the two readers agreed, respectively. EA and 
CA surpassed the FDA limit of 90% for all 14 drugs well be-
fore the end of incubation (18–19 h). Note that EA/CA be-
gan near 0% at the beginning of incubation for drugs 
against which growth/resistance was common such as dap-
tomycin, whereas EA/CA began higher for drugs against 
which growth/resistance was rare, such as rifampin. 
Maj rate remained below the FDA limit of 3% for 11 of 12 
possible drugs, and the drug for which it exceeded 3% (tri-
methoprim/sulfamethoxazole or Bactrim) was due to a sin-
gle major error. It was not possible to calculate maj rate for 
two drugs (gatifloxacin and erythromycin) because re-
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sistance to these drugs was not observed for any clinical iso-
lates. The maj rate for each of the other 12 drugs is plotted, 
but those that never move above 0% obscure one another. 
Vmj rate dropped below the FDA-permitted maximum of 
3% before the end of incubation for 9 of 13 possible drugs. 
Again, the four drugs for which the system did not meet the 
Figure 4. (a) Average time required for the panel of neural networks to make a correct turbidity prediction for each drug on blind 
testing isolates of Staphylococcus aureus. 95.03% of all turbid wells were correctly identified by the network, with the average turbid 
well requiring 5.72 h of incubation for automated detection. (b) Average well accuracy over the course of incubation. 90% of all wells 
were correctly classified after 7 h, and 95% after 10.5 h of incubation. 
FDA limit (levofloxacin, ciprofloxacin, trimethoprim/sulfamethoxazole, and quinupristin/dalfopristin) each experienced only 
a single very major error. It was not possible to calculate vmj rate for vancomycin because no clinical isolates exhibited re-
sistance to it. Using the data from Figure 5, the incubation times required to meet/surpass the FDA limits for EA/CA/maj/vmj 
rate are listed in Table 1. The system met the FDA-defined criteria for EA/CA for all 14 drugs after an average of 6.13 h and 
6.98 h, respectively. The system met FDA criteria for major and very major error rates for 11 of 12 possible drugs after an 
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average of 4.02 h, and 9 of 13 possible drugs after an average of 9.39 h, respectively. These results are in line with the perfor-
mance on the validation data, demonstrating that the panel of networks is not overfit (Figures S5, S6, and Table S3). 
Figure 5. Essential agreement (EA), categorical agreement (CA), major error (maj) rate, and very major error (vmj) rate as a function 
of the incubation time for different antibiotics on blind testing isolates of Staphylococcus aureus. The second column in each plot 
legend indicates the number of samples for the corresponding metric (total number of valid samples for EA/CA, number of suscep-
tible samples for maj rate, and number of resistant samples for vmj rate). EA and CA surpass the FDA limit of 90% for all 14 drugs 
well before the end of incubation. Maj rate remained below the FDA-permitted maximum of 3% for 11 of 12 possible drugs and vmj 
rate dropped below the FDA maximum of 3% before the end of incubation for 9 of 13 possible drugs.
The curve labeled “panel of networks” corresponds to the 
composite panel of neural networks, whereas “single net-
work” refers to the best individual network (by validation 
loss) from the panel. Three additional panels of networks 
were also generated (from a sample size of 50 nine-fold 
cross-validations as before) using only images of a single il-
lumination color (red, green, or blue). Finally, a logistic re-
gression model was tested, as well as a simple threshold-
based model, which classifies the well as turbid if at least 
two of the three most recent images have at least one fiber 
intensity lower than the threshold of 0.8876. This threshold 
value was determined by optimizing accuracy over the 
training patient plates. 
The panel of networks showed the best performance 
across all four metrics, but there was only a slight penalty 
in EA and maj rate by using a single network. The networks 
that used only images of a single color fared considerably 
worse than the network or panel of networks using all three 
colors. Among the three colors we would not expect a large 
difference, but green did perform the best, possibly since it 
used twice the number of pixels per fiber due to the Bayer 
filter array on the CMOS image sensor. The logistic regres-
sion performed better than the single-color networks, but 
not as well as the three-color network or panel of networks. 
The threshold-based simple approach was the worst per-
former, with under 90% CA and over 10% vmj rate. Figures 
S1 and S2 show many examples of wells with predictions 
from the panel of networks, logistic regression, and thresh-
old approach, demonstrating where the simpler models 
both failed to identify weak growth and falsely identified 
growth in non-turbid wells. Figures S7a,b show additional 
fiber intensities and network predictions for instances of a 
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“skipped” well and wells with bubbles, respectively. These 
are well-known phenomena in AST and the network gave 
correct turbidity predictions in each case. 
 
Discussion 
Drug 
Essential 
Agree-
ment 
Categori-
cal 
Agreement 
𝒏total 
Major error 
rate 
𝒏susceptible 
Very major error 
rate 
𝒏resistant 
Oxacillin + 2% 
NaCl 
4.25 4.25 29 3.5 21 9.25 8 
Levofloxacin 5.5 5.25 29 2.5 17 N/A 12 
Tetracycline 5 5 28 2.5 23 5.75 5 
Gatifloxacin 5 4.5 30 - 0 10.5 13 
Daptomycin 5.5 10.25 32 2.5 3 16 29 
Gentamicin 2.5 2.5 33 18.25 31 5 2 
Ciprofloxacin 5.25 5.25 29 2.5 17 N/A 12 
Penicillin 9.5 5.5 33 2.5 7 16.75 26 
Erythromycin 8.75 8.75 30 - 0 9.25 10 
Vancomycin 5 14 32 2.5 19 - 0 
Rifampin 2.5 2.5 30 2.5 28 4.75 2 
Quinupristin/ 
dalfopristin 
6.75 14 26 2.5 23 N/A 1 
Clindamycin 8.25 4 25 2.5 21 7.25 3 
Trimethoprim/ 
sulfamethoxazole 
12 12 28 N/A 27 N/A 1 
AVERAGE 6.13 6.98  4.02  9.39  
Table 1. Incubation time (h) required to meet FDA criteria by drug for blind testing isolates of S. aureus.
Our system demonstrates the ability to detect turbidity and 
quantify resistance much sooner than the gold standard 
method, which requires at least 18–24 h. On the blind test-
ing data, the system made only one major error and four 
very major errors across all 33 patients with 14 drugs each. 
The fiber intensities and network predictions for the wells 
corresponding to each of these errors are shown in Figures 
S8–10 along with an image of the wells captured with a 
smartphone camera at the end of incubation. Each drug for 
which our system exceeded the FDA-defined limit of 3% for 
maj or vmj rate only experienced a single error. With addi-
tional testing samples, the maj/vmj rates may drop below 
3% for all drugs. In addition, the FDA defines major and very 
major errors as misclassification of a susceptible/resistant 
organism as resistant/susceptible. However, the one major 
error and one of the four very major errors from the net-
work’s predictions did not include a predicted susceptibil-
ity because the predicted MIC was undefined (known as a 
“skipped well”). We report these instances as major/very 
major errors, but they can be thought of as inconclusive re-
sults, for which a human could be notified to read the MIC 
manually or decide to repeat the test. 
The performance of the system demonstrates the poten-
tial to enable automated, cost-effective susceptibility test-
ing with early results in resource-limited laboratories. Un-
like the gold standard BMD method, our system does not re-
quire a full 18–24 h incubation or a trained technologist for 
plate readout and, unlike microscopy-based solutions, it re-
quires no mechanical scanning components or bulky, costly 
hardware. Cost and access to trained personnel are primary 
factors that currently limit the reach of AST in developing 
regions. Our system also uses standard 96-well plates, 
which would allow it to more rapidly integrate with typical 
clinical workflow. In addition, because the system autono-
mously captures images during incubation without the 
need to remove the plate from the incubator, early results 
for drugs showing strong resistance can be sent to the phy-
sician as soon as they are available, while the device contin-
ues to monitor growth in the wells with the remaining 
drugs. Due to the phenotypic nature of our sensing mecha-
nism, we believe it can be extended to almost any type of 
bacteria, or other plate-based tasks such as enzyme-linked 
immunosorbent assays (ELISA) and culture samples. The fi-
ber-based subsampling of the wells could enable the 
streamlining of daily laboratory tasks with robust, auto-
mated readout in a compact form factor. 
From Figure 6, it is clear that the panel of neural networks 
gave the best performance on the blind testing data, demon-
strating an ability to discern nuanced patterns in fiber in-
tensities. While a desktop computer was used to train the 
panel of networks, due to the rapidly decreasing cost of 
computation in embedded systems, future training could be 
performed on the Raspberry Pi or other compact device. In 
addition, a single network showed only a modest drop in 
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performance, which could shorten computation time. Be-
cause the networks were not given knowledge of the well, 
drug, or concentration when making predictions, they also 
learned a model of turbidity that is quite general, instead of 
overfitting to the specifics of the plate or drugs used in the 
experiments. Because the second technologist who made 
ground truth readings for the testing data was not used for 
the training/validation data, the system demonstrated an  
Figure 6. Essential agreement (EA), categorical agreement (CA), major error (maj) rate, and very major error (vmj) rate averaged 
over all the drugs for various models for blind testing data. “Panel of networks” refers to the panel of nine neural networks trained 
via cross-validation. “Single network” is only the best of the nine networks (by validation loss). “Panel (red/green/blue)” is a panel 
of networks that only uses images of the specified color. “Threshold” is a simple threshold-based approach in which a well is classi-
fied as turbid if fiber intensities fall below a specified threshold (see Methods section). 
ability to generalize beyond the specific patterns of an indi-
vidual human reader. 
 
Conclusion 
The presented system demonstrates the ability to conduct 
AST much faster than the gold standard method of incuba-
tion for 18–24 h followed by visual inspection. The time sav-
ings is critical to ensuring patients receive the most effec-
tive, targeted antibiotics and to limit the global rise in anti-
microbial resistance. Our system also removes the need for 
a trained medical technologist and integrates with the 
standard clinical workflow using an incubator and 96-well 
microplates. The system is cost-effective due to the use of 
off-the-shelf components and could be particularly suited to 
resource-limited laboratories in developing regions, where 
antimicrobial resistance is predicted to cause the most 
deaths and access to trained personnel is limited. 
 
Methods 
Imaging System 
The AST system illumination is composed of two 8x8 arrays 
of individually addressable RGB LEDs (Adafruit Industries) 
whose pulse width modulation brightness is set by 2 Trin-
ket microcontrollers (Adafruit Industries). The system con-
tains 2016 0.75 mm plastic optical fibers (CK-30, Industrial 
Fiber Optics Inc.), which were epoxied and polished with a 
handheld polishing tool. The two common fiber bundles 
each contain fibers for half of the 96-well plate. They are 
each imaged by the combination of a 10.0 mm diameter × 
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50.0 mm focal length plano-convex lens (Edmund Optics) 
and a Raspberry Pi Camera Module V2 (Newark) with 1.12 
µm × 1.12 µm pixel size. The two cameras are controlled by 
two Raspberry Pi 3 Model B computers. Images are cap-
tured in raw 10-bit format at 8.1 MP. 
Image Processing and Neural Network 
Image processing was performed in MATLAB (MathWorks) 
and neural network training/testing was performed in Py-
thon using TensorFlow 1.14 (Google). The logistic regres-
sion model was created in Python with the scikit-learn li-
brary (David Cournapeau), using the saga solver, the elas-
ticnet penalty with an L1 ratio of 0.9, and an inverse regu-
larization strength of C = 2. 
Clinical Testing 
All experiments were performed at the UCLA Clinical Micro-
biology Laboratory. The AST system was placed inside a 2-
cubic foot incubator (Binder) for the duration of the exper-
iments. Initial experiments were performed using the 
ATCC43300 strain of MRSA in 47 plates. Confirmed clinical 
S. aureus isolates collected at the UCLA Clinical Microbiol-
ogy Laboratory were tested on the platform for the remain-
der of the experiments. S. aureus isolates were prepared to 
a 0.5 McFarland standard in sterile water and 50 µL of this 
suspension was transferred into 11 mL of Mueller Hinton 
Broth. The dilution was inoculated into 96-well microplates 
(100 μL of bacterial suspension per well) containing a com-
mercially available Gram-positive antibiotic panel (Sensiti-
tre Gram Positive MIC plates, ThermoFisher Scientific) 
shown in Table S4. Following bacterial inoculation, single 
plates were loaded into the incubator for 18–19 h. At the 
end of incubation, plates were removed and turbidity was 
manually assessed by trained personnel. For training/vali-
dation data (51 clinical plates), plates were read by a single 
reader. For testing data (33 clinical plates), plates were read 
by two readers to assess and mitigate interpersonal vari-
ances among readers. MIC was determined by identification 
of the first well without turbidity for increasing drug con-
centrations. Interpretation of susceptibility was deter-
mined in accordance to Clinical & Laboratory Institute 
Standards 2019.8 
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